These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15767976)

  • 1. Solifenacin and darifenacin for overactive bladder.
    Med Lett Drugs Ther; 2005 Mar; 47(1204):23-4. PubMed ID: 15767976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevating our therapeutic expectations in overactive bladder.
    Sand PK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):8-11. PubMed ID: 15543927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darifenacin in the treatment of overactive bladder.
    Parsons M; Robinson D; Cardozo L
    Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
    But I; Goldstajn MS; Oresković S
    Coll Antropol; 2012 Dec; 36(4):1347-53. PubMed ID: 23390832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
    Kershen RT; Hsieh M
    Curr Urol Rep; 2004 Oct; 5(5):359-67. PubMed ID: 15461912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
    Millard RJ; Halaska M
    Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of solifenacin in the treatment of overactive bladder.
    Robinson D; Cardozo L
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1339-48. PubMed ID: 15461562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L; Dixon A
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.